Moreover, there are several ongoing trials for COVID-19 patients to target the macrophage activation to reduce the hyper inflammation state inside the patients, where the drugs are targeted against other pro-inflammatory cytokines and chemokine such as IL-1ß, TNF-α, IFN-γ and CCR5 [270]. Here, IL1A is linked to COVID-19.